Incyte | INCY - Interest Income


Incyte reported $38.12M in Interest Income for its fiscal quarter ending in June of 2026.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.06M 277K Mar/2026
Agios Pharmaceuticals USD 10.8M 1.62M Mar/2026
Alnylam Pharmaceuticals USD 26.6M 32K Mar/2026
BioCryst Pharmaceuticals USD -0.13 3.59M Dec/2024
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Eli Lilly USD 65M 25M Sep/2025
Exelixis USD 14.21M 1.92M Jun/2026
Gilead Sciences USD 95M 0 Mar/2026
Incyte USD 38.12M 4.43M Jun/2026
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
MacroGenics USD 1.55M 26K Mar/2026
Merck USD 35M 34M Mar/2026
Moderna USD 72M 2M Mar/2026
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD -0.04 115M Jun/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 183.3M 200K Jun/2026
Sarepta Therapeutics USD 7M 1.74M Mar/2026
Ultragenyx Pharmaceutical USD 6M 512K Mar/2026
Vertex Pharmaceuticals USD 120.6M 5.8M Jun/2026